Related Experiment Video
Updated: Jun 4, 2026

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
Published on: December 1, 2023
Glatiramer acetate treatment of multiple sclerosis: an immunological perspective
Michael K Racke1, Amy E Lovett-Racke
1Department of Neurology, The Ohio State University Medical Center, Columbus, OH 43210-1228, USA. michael.racke@osumc.edu
Abstract:
Glatiramer acetate (GA) has been used as an immunomodulatory agent for the treatment of relapsing-remitting multiple sclerosis (MS) in the United States since 1996. It is currently one of two first-line agents for use in the treatment of relapsing-remitting MS. GA was the first agent to be used in the treatment of MS that was developed using the animal model of MS called experimental autoimmune encephalomyelitis. In this commentary, we examine the development of GA as a treatment for MS and discuss its mechanism of action as suggested by recent studies using modern immunologic methods.
More Related Videos
Related Concept Videos
Multiple Sclerosis l: Introduction
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis ll: Pathophysiology
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

